BBiApt was found to bind with the extracellular domains of membrane proteins of MUC1- or CD16-positive cells (Figure 5), and could recruit more CD16-positive immunocytes around the MUC1-positive tumor cells (Figure 6). Here, MUC1 is linked to neoplasm.